High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: A pilot, randomized, double-blind, placebo-controlled trial

American Journal of Clinical Nutrition

Volumn 96, Issue 3, 2012, Pages 672-679

  Alvarez, Jessica A ^a   Law, Jennie ^a   Coakley, Kathryn E ^c   Zughaier, Susu M ^b   Hao, Li ^f   Salles, Khadijeh Shahid ^e   Wasse, Haimanot ^a   Gutiérrez, Orlando M ^d   Ziegler, Thomas R ^a   Tangpricha, Vin ^a,c,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pediatrics   (United States)

^c EMORY UNIVERSITY   (United States)

^d University of Alabama at Birmingham   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

^f Atlanta Veterans Affairs Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE DETERMINATION; HUMAN; HYPERTENSION; MALE; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; URINALYSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED; CALCIFEDIOL; CHOLECALCIFEROL; DIET; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GEORGIA; HOSPITALS, VETERANS; HUMANS; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, SECONDARY; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PILOT PROJECTS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; VITAMIN D DEFICIENCY;

EID: 84865334803     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.040642     Document Type: Article

References (49)

1. Castro AF, Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53(3 suppl 3):S46-55.
2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011;80:1258-70.
3. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
4. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-21.
5. Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001;38(5 suppl 5):S20-33.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 suppl 3):S1-201.
7. Alvarez JA, Wasse H, Tangpricha V. Vitamin D supplementation in chronic kidney disease: a systematic review. Dermato-Endocrinology 2012;4 (in press). Available from: http://www.landesbioscience.com/journals/dermatoendocrinology/ toc/volume/4/issue/2/.
8. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D3 is more potent than vitamin D2 in humans. J Clin Endocrinol Metab 2011;96:E447-52.
9. Khazai NB, Judd SE, Jeng L, Wolfenden LL, Stecenko A, Ziegler TR, Tangpricha V. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab 2009;94:2037-43.
10. 2. Am J Clin Nutr 1998;68:854-8.
11. Petchey WG, Johnson DW, Isbel NM. Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton) 2011;16:351-67.
12. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther (Epub ahead of print 17 August 2011).
13. Judd SE, Tangpricha V. Vitamin d therapy and cardiovascular health. Curr Hypertens Rep 2011;13:187-91.
14. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
15. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931-42.
16. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-14.
17. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:299-306.
18. Gutiérrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 2010;5:1710-6.
19. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-9.
20. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
21. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
22. Bross R, Noori N, Kovesdy CP, Murali SB, Benner D, Block G, Kopple JD, Kalantar-Zadeh K. Dietary assessment of individuals with chronic kidney disease. Semin Dial 2010;23:359-64.
23. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1144-51.
24. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75:88-95.
25. 3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008;14: 10-7.
26. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007;50:59-68.
27. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012;59:58-66.
28. Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, Cadena A, Gelfond J, Kasinath B. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? Clin Nephrol 2010;73:276-85.
29. Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, Wells D, Aitkenhead H, Manickavasagar B, Van't Hoff W, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012;7:216-23.
30. Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, Leonard MB. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 2009;4:186-94.
31. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 2012;7:624-31.
32. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol 2010;163:825-31.
33. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007;293:F1577-83.
34. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
35. Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007;22:3202-7.
36. Leu M, Giovannucci E, Vitamin D. Epidemiology of cardiovascular risks and events. Best Pract Res Clin Endocrinol Metab 2011;25:633-46.
37. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005;111:697-716.
38. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010;5:905-11.
39. Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 2008;3:1800-6.
40. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007;49:1278-84.
41. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, Kavtaradze N, Uphoff I, Hooper C, Tangpricha V, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011;58:186-92.
42. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84.
43. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, de Jong PE, El-Nahas M, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011;79:1331-40.
44. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77.
45. Isakova T, Gutiérrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011;21:295-302.
46. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-55.
47. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51.
48. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012;21:72-9.
49. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011;79:715-29.